BioNano Genomics Inc vs Pinterest Inc — how do they compare? BioNano Genomics Inc trades at $1.24 (market cap $13.66M), while Pinterest Inc trades at $22.97 (market cap $13.45B). The key difference: Pinterest Inc is far larger — about 984.6× BioNano Genomics Inc's market cap, and Pinterest Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | PINS | |
|---|---|---|
Market Cap | $13.66M | $13.45B |
Sector | Health | Media |
52-Week High | $4.92 | $37.95 |
52-Week Low | $1.06 | $15.42 |
Enterprise Value | $16.26M | $13.37B |
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Pinterest (PINS) trades at $22.93, down 5.91% over 24 hours, reflecting market disappointment despite strong Q2 2026 earnings beats. Revenue growth remains robust at 18% year-over-year, driven by AI-powered ads and record user growth to 640 million monthly active users. Technical indicators show a bullish moving average signal but neutral oscillators, with key support at $23. Recent news highlights a federal securities lawsuit investigation and CFO stock sales, adding volatility.
The outlook is mixed: solid fundamentals and a $28.69 analyst price target suggest upside, but competitive ad markets and lukewarm Q3 guidance pose risks. Investor sentiment is cautious despite bullish analyst consensus, with the stock's high P/E ratio of 69.85 requiring sustained growth to justify valuations. Key opportunities lie in international expansion and AI monetization, while legal and competitive pressures are headwinds.
Trailing returns across standard periods
Latest headlines on both assets
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →